IFCC Task Force on COVID-19
Membership
| Name | Position | Country | Term | Time in Office |
| Giuseppe Lippi | Chair | IT | 1st | 2020 03 - 2022 12 |
| Andrea Horvath | Member | AU | 1st | 2020 03 - 2022 12 |
| David Koch | Member | US | 1st | 2020 03 - 2022 12 |
| Nicasio Mancini | Member | IT | 1st | 2020 04 - 2022 12 |
| Sunil Sethi | Member | SG | 1st | 2020 03 - 2022 12 |
| Cheng-Bin Wang | Member | CN | 1st | 2020 04 - 2022 12 |
| KY Yuen | Member | HK | 1st | 2020 04 - 2022 12 |
NEW: SARS-COV-2 Variants Working Group
Introduction
The leading objectives of this TF encompass the provision of regular updates on epidemiology, pathogenesis and laboratory diagnostics of COVID-19, the development of practical recommendations for harmonizing the use of diagnostic tests for COVID-19 and biosafety measures for managing the specimens, as well as the organization of international studies to improve the knowledge on pathogenesis, diagnostics and therapeutic management of COVID-19.
Terms of reference
- Establish and maintain an IFCC e-learning platform on COVID-19 (“IFCC Information Guide on COVID-19”), which provides regular updates on epidemiology, pathogenesis and laboratory testing of COVID-19;
- Provide tentative guidance and consensus documents for harmonizing the use of diagnostic and serological tests for COVID-19;
- Provide tentative guidance for harmonizing biosafety measures during management of COVID-19 specimens by clinical laboratories;
- Address clinical, technical and organizational perspectives of laboratory-based and POC testing in COVID-19 patients and provide guidelines/recommendation when feasible;
- Integrate data on COVID-19 laboratory abnormalities from all over the world, and promoting or coordinating new studies;
- Evaluate opportunities, risks and safety of using non-conventional biological materials for diagnosing COVID-19;
- Establish and maintain efficient distance learning channels, with organization of webinars and providence of other informative material;
- Maintain a repository of scientific articles on laboratory testing for diagnosing, prognosticating and monitoring COVID-19.
For latest updated, visit:
- IFCC Information Guide on COVID-19 - May 31st 2021 updates
- IFCC Interim Guidelines on COVID-19 Testing in Clinical Laboratories – last update April 2021
Experts Consultants
| Name | Affiliation |
| Massimo Clementi | University Vita-Salute San Raffaele, Milan (Italy) |
| William D. Rawlinson | The Prince of Wales Hospital, Randwick (Australia) |
Corresponding Members nominated by IFCC Regional Federations
| Name | Regional Federation |
| Osama Najjar | Arab Federation of Clinical Biology (AFCB) |
| Rajiv Erasmus | African Federation of Clinical Chemistry (AFCC) |
| Gye Cheol Kwon | Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB) |
| María Elizabeth Menezes | Latin-American Confederation of Clinical Biochemistry (COLABIOCLI) |
Corresponding Members nominated by IFCC Corporate Members
| Name | Corporate Members |
| Robert Mueller | ABBOTT Diagnostics |
| Marc Leportier | BECKMAN COULTER |
| Matthias Grimmler | DIASYS Diagnostic Systems |
| Maria-Magdalena Patru | ORTHO CLINICAL DIAGNOSTICS |
| Fabio Rota | SENTINEL CH |
| Krishna Singh | SIEMENS Healthineers |
| Ran Xu | SNIBE |
| Maurizio Gramegna | TECHNOGENETICS |
Chair's Contact
Prof. Giuseppe Lippi
Full Professor of Clinical Biochemistry, University of Verona
Director, Service of Laboratory Medicine, University Hospital of Verona
Secretary of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Executive Editor-in-Chief, Annals of Translational Medicine
Editor in Chief, Journal of Laboratory and Precision Medicine
Associate Editor, Clinical Chemistry and Laboratory Medicine
Associate Editor, Seminars in Thrombosis and Hemostasis
E-mail: giuseppe.lippi@univr.it